Receive The Newest Study Notifications

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

by Lance Smith | Dec 13, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Presentation Will Provide Overview of Ongoing Clinical Trial of Salarius’ Lead Drug Candidate, Seclidemstat, in Ewing Sarcoma HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting the...

First patient dosed in ProQR retinitis pigmentosa trial

by Lance Smith | Dec 13, 2019 | Study Scavenger Clinical Trial Recruitment Platform

ProQR Therapeutics has dosed the first patient in a phase 1/2 trial of QR-1123, its treatment candidate for autosomal dominant retinitis pigmentosa, according to a press release. The first-in-human AURORA trial, consisting of single-dose and multiple-dose escalation...

Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome

by Lance Smith | Dec 12, 2019 | Study Scavenger Clinical Trial Recruitment Platform

GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) — Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that the first patient has been dosed in a Phase 2b trial of...

MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

by Lance Smith | Dec 12, 2019 | Study Scavenger Clinical Trial Recruitment Platform

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing...

G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

by Lance Smith | Dec 12, 2019 | Study Scavenger Clinical Trial Recruitment Platform

RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor...

Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

by Lance Smith | Dec 12, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a...